Selegiline shortage: Causes and costs of a generic drug shortage

Neurology

Volumn 73, Issue 3, 2009, Pages 213-217

  Dorsey, E R ^a,b,c   Thompson, J P ^b,d   Dayoub, E J ^b,e   George, B ^b,f   Saubermann, L A ^a,b   Holloway, R G ^b,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Department of Neurology ^*  (United States)

^c Strong Health   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e ANALYSIS GROUP   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; SELEGILINE; ANTIPARKINSON AGENT;

ARTICLE; CANADA; DRUG CAPSULE; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SUBSTITUTION; DRUG UTILIZATION; HEALTH ECONOMICS; HUMAN; MARKET; MICROCAPSULE; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; DRUG CONTROL; ECONOMICS; HEALTH CARE DELIVERY; LEGAL ASPECT; STANDARD; STATISTICS;

ANTIPARKINSON AGENTS; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; PARKINSON DISEASE; PRESCRIPTIONS; SELEGILINE;

EID: 68949196137     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ae7b04     Document Type: Article

References (17)

1. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183. (Pubitemid 23021504)
2. The Parkinson Study Group. Effects of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
3. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995. (Pubitemid 44044780)
4. American Society of Health-System Pharmacists. Current shortages. Available at: http://www.ashp.org/s-ashp/bulletin.asp?id=334&CID= 1500&DID =1544&sort=0. Accessed February 8, 2008.
5. Jackevicius CA, Tu JC, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med 2008;358:1819-1828. (Pubitemid 351581194)
6. IMS Health. IMS National Prescription Audit™, 02/200212/2007.
7. Extracted January 2008. Available at http://us.imshealth.com/nextgen/enh- NPA.htm. Accessed June 10, 2009.
8. Medicare: The official U.S. government site for people with medicare. Medicare prescription drug plan finder. Available at: http://www.medicare.gov/ MPDPF/Public/Include/DataSection/Questions/MPDPFIntro.asp. Accessed August 1, 2008.
9. Drugstore.com. The uncommon drugstore. Available at: http://www. drugstore.com. Accessed January 6, 2009.
10. Fox ER Tyler LS. Managing drug shortages: seven years' experience at one health system. Am J Health Syst Pharm 2003;60:245-253.
11. Mylan Laboratories Inc. 2006 Annual Report. Canonsburg, PA; Mylan Laboratories Inc.: 2006.
12. JensenV,KimzeyLM,GoldbergerMJ.FDA'sroleinresponding-drugshortages. AmJHealthSystPharm2002;59:1423-1425.(Pubitemid34887075)
13. Wang SS. Teva to buy US generic rival Barr for $7.46 billion: Israeli firm to get improved position in emerging zones. Wall Street Journal. July 19, 2008.
14. Jack A. A bigger dose: why generic drug producers are bulking up. Financial Times. July 22, 2008.
15. Press TA. Executive charged with lying in Plavix case. New York Times. April 23, 2008.
16. Federal Food, Drug, and Cosmetic Act. 21 U.S.C. Section 506 (c), 1997.
17. Wellman GS. National supply-chain survey of drug manufacturer back orders. Am J Health Syst Pharm 2001;58: 1224-1228.